Top Medical News
an hour ago
Combination sequential therapy appears to be a beneficial alternative to monotherapy, leading to improved survival in patients with systemic sclerosis (SSc)-related pulmonary arterial hypertension (PAH), a study has shown.
Stephen Padilla, Yesterday
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Yesterday
The use of antipsychotics may increase the risk of head injuries and traumatic brain injuries (TBIs) among elderly adults with Alzheimer’s disease (AD), a recent Finland study has found.
2 days ago
Low albumin levels are linked to high on-aspirin platelet reactivity (HAPR) among patients with stable coronary artery disease (CAD), a new study has found.
2 days ago
The timing of direct oral anticoagulants (DOACs) administration, either within 3 days or ≥4 days of stroke onset, in patients with nonvalvular atrial fibrillation (AF) does not alter the risk of adverse outcomes such as stroke or systemic embolism, major bleeding, and death, as shown in a recent study.
3 days ago
Exposure to high-dose gentamicin in the neonatal period bears no risk of hearing loss in the conventional midfrequencies and extended high-frequencies, a study has found.
Roshini Claire Anthony, 3 days ago

The choice of stress ulcer prophylaxis strategy – proton pump inhibitor (PPI) or histamine-2 receptor blocker (H2RB) – did not affect mortality within 90 days of admission to the intensive care unit (ICU), according to results of the PEPTIC* trial presented at the recent Critical Care Reviews Meeting (CCR20).

Special Reports
23 Jan 2020
Bumrungrad International Hospital was founded in 1980 and has since grown to become one of the most reputable hospitals in the region. The recipient of numerous international awards and accreditations, Bumrungrad International is one of the largest private hospitals in Southeast Asia, catering to over 1.1 million patients from over 190 countries annually.

In an exclusive interview with MIMS, Kenny Lim, Chief Information Technology Officer of Bumrungrad International Hospital shared his views on how the hospital has continued to improve its services to patients with particular emphasis on the use of clinical decisions support tools.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
29 Nov 2019
Fenofibrate 145 mg, simvastatin 20 mg FC tab
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Conference Reports
Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Stephen Padilla, 24 Jan 2020
Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.
Jairia Dela Cruz, 24 Jan 2020
Most patients with moderately to severely active ulcerative colitis and Crohn’s disease on vedolizumab persist with their treatment for up to 5 years, according to a posthoc analysis of the phase III GEMINI long-term safety (LTS) study presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Annual Meeting.
Audrey Abella, 23 Jan 2020
The TURANDOT* and TURANDOT II** studies confirm the efficacy of the monoclonal immunoglobulin G2 anti-MAdCAM-1*** antibody ontamalimab to induce remission in patients with ulcerative colitis (UC).
Audrey Abella, 22 Jan 2020
The oral Janus kinase inhibitor tofacitinib appears to have no benefit for the extraintestinal manifestations* (EIMs) of moderate-to-severe ulcerative colitis (UC), according to data from the OCTAVE** clinical programme presented at AIBD 2019.
Pearl Toh, 17 Jan 2020
Children with inflammatory bowel disease (IBD) were more likely to use psychotropic medications than those without the disease, according to a study presented at AIBD 2019 Conference.
Pearl Toh, 16 Jan 2020
The adalimumab biosimilar BI 695501 shows similar efficacy and safety profile as its reference product in patients with moderate-to-severe Crohn's disease (CD), according to a phase III study recently presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Conference.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download